CSBio CSBio

X
[{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Zukunftsfonds Heilbronn","pharmaFlowCategory":"D","amount":"$72.2 million","upfrontCash":"Undisclosed","newsHeadline":"Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Elevar Therapeutics"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz\u00ae Regenerative Immunotherapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Creative Medical Technology"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TwoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy and Safety of Two Novel CKD Treatment Candidates","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"twoXAR Pharmaceutical"},{"orgOrder":0,"company":"Telara Pharma","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Telara Pharma"},{"orgOrder":0,"company":"Nephraegis Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nephraegis Therapeutics"},{"orgOrder":0,"company":"Tribune Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tribune Therapeutics Launches to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Tribune Therapeutics"},{"orgOrder":0,"company":"Sinovent","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"$561.0 million","upfrontCash":"$12.0 million","newsHeadline":"Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sinovent"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Q32 Bio"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Files for Regulatory Clearance to Begin Phase 1\/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Q32 Bio"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Zhejiang Ausun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Saniona","sponsor":"University of Arhus","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona\u2019s Preclinical Candidate SAN903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Saniona"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Transcenta Holding"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic Uremic Syndrome with First-in-class CRISPR-based medicine","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Eligo Bioscience"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Revelation Biosciences"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Maze Therapeutics"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Revelation Biosciences"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"IGAN Biosciences"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for Lupkynis\u00ae in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Revelation Biosciences"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Purespring Therapeutics"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$30.0 million","newsHeadline":"Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Teijin Pharma"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Guangdong Academy of Medical Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Everest Medicines"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS\u00ae in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Algernon Pharmaceuticals"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"United Therapeutics to Acquire Miromatrix Medical","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"$91.0 million","newsHeadline":"United Therapeutics to Acquire Miromatrix Medical","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"United Therapeutics"},{"orgOrder":0,"company":"Miromatrix Medical","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Miromatrix Medical"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$20.4 million","newsHeadline":"CalciMedica Announces Private Placement of up to Approximately $55 Million","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"CalciMedica"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The net proceeds will be used for the clinical development of the Auxora (zegocractin), which is a small molecule CRAC channel inhibitor and are also planning for Phase 2 for the treatment of acute kidney injury.

            Lead Product(s): Zegocractin

            Therapeutic Area: Nephrology Product Name: Auxora

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Deerfield Management

            Deal Size: $55.0 million Upfront Cash: $20.4 million

            Deal Type: Private Placement January 22, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Miromatrix Medical

            Contact Supplier
            • Deals
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            The acquisition of Miromatrix will expand United Therapeutics’ platform of organ manufacturing programs and regenerative medicine and upon the achievement of clinical development milestone to Miromatrix’s development-stage, manufactured kidney product known as mirokidney™.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nephrology Product Name: Mirokidney

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: United Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition December 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The acquisition of Miromatrix will expand United Therapeutics’ platform of organ manufacturing programs and regenerative medicine and upon the achievement of clinical development milestone to Miromatrix’s development-stage, manufactured kidney product known as mirokidney™.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nephrology Product Name: Mirokidney

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: United Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, United Therapeutics gains access to Miromatrix’s development-stage, fully-implantable manufactured kidney product known as mirokidney.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nephrology Product Name: Mirokidney

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: United Therapeutics

            Deal Size: $91.0 million Upfront Cash: $91.0 million

            Deal Type: Acquisition October 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NP-251 (repirinast), company’s lead candidate for the treatment of chronic kidney disease, binds to receptors on mast cell and prevents their degranulation. Repirinast originally developed by Mitsubishi was sold in Japan under the brand name Romet™ for the treatment of Asthma.

            Lead Product(s): Repirinast

            Therapeutic Area: Nephrology Product Name: NP-251

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Lupkynis (voclosporin) is a calcineurin-inhibitor of calcineurin. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. Currently being developed for lupus nephritis.

            Lead Product(s): Voclosporin,Mycophenolate Mofetil,Undisclosed

            Therapeutic Area: Nephrology Product Name: Lupkynis

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement is for the comprehensive strategic cooperation with Guangdong Academy of Medical Sciences in renal disease research, scientific innovation and translational studies.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nephrology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Guangdong Academy of Medical Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Teijin will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize an investigational small molecule candidate for proteinuric kidney diseases. The candidate is believed to impact the pathogenesis of multiple kidney diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nephrology Product Name: Undislcosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $230.0 million Upfront Cash: $30.0 million

            Deal Type: Licensing Agreement March 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Purespring’s Adeno Associated Virus (AAV) based gene therapy presents a lower-dose, local delivery approach which maximizes both safety and efficacy, as well as lowering the cost of goods.

            Lead Product(s): AAV-based Gene Therapy

            Therapeutic Area: Nephrology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Charles River Laboratories International

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            REVTx-300 is a inhibitor of TGF-b, formulated for systemic administration of PHAD and is being developed as a potential therapy for CKD, AKI, myocarditis and NASH.

            Lead Product(s): REVTx-300

            Therapeutic Area: Nephrology Product Name: REVTx-300

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY